Celltrion Group Chairman and founder Seo Jung-jin said Tuesday that the company is preparing for new US tariffs by moving closer to acquiring a biologics manufacturing facility in the United States — a move that would give Celltrion greater access to a market Seo framed as “indispensable.”
“The US is simply too big a market to walk away from, and we’re aiming to eliminate uncertainty in our US sales,” said Seo during a livestreamed press conference Tuesday. “If the US government wants drugs to be made in the US, then our plan is to produce them there accordingly.”
Read the article.